
Noted Vaccine Researcher and Leader Kate O'Brien Awarded Sabin's Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O'Brien, MD, MPH, for her research on the pneumococcal vaccine and leadership in global vaccine research and access, and its Rising Star Award to dedicated physician and public health specialist Livancliff Mbianke, MD, MPH, of Cameroon. The awards were presented at a ceremony in the National Academy of Sciences building in Washington D.C.
O'Brien is a pioneering global health leader whose innovative work in vaccine access and policy has transformed immunization programs worldwide.
'I am honored to award the Sabin Gold Medal to Dr. O'Brien for her extensive scientific and humanitarian work, which has significantly contributed to the development, licensure, and global distribution of critical immunizations,' says Amy Finan, Sabin's chief executive officer. 'The breadth and scope of her work — in addition to her leadership in advancing the availability of vaccines for everyone, everywhere — has saved millions of lives around the world.'
O'Brien's interest in vaccines and preventable illness began during her early career as a research pediatrician in Port-au-Prince, Haiti, where almost a third of children admitted to the hospital she worked at died, often from vaccine-preventable diseases. Returning to the U.S. to pursue her infectious disease fellowship, Master of Public Health, and training as an epidemiologist, she then worked for the Johns Hopkins Center for American Indian Health and led groundbreaking clinical trials on the pneumococcal vaccine to establish the vaccine's performance and impact on both disease and on colonization to achieve both individual and population-level protection. O'Brien was appointed Director of Infectious Disease at the Center and led research on vaccine development and implementation for vaccine-preventable diseases disproportionately affecting Indigenous populations. Her work in large-scale vaccine impact studies and clinical trials has been instrumental in the licensure, introduction and global use of vaccines against pneumococcal disease, rotavirus, influenza, and respiratory syncytial virus (RSV).
.
O'Brien continued her leadership in vaccine development, access, and research in her position as the Executive Director of the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. She has served on WHO's Strategic Advisory Group of Experts on Immunization (SAGE) and on the board of Gavi, the Vaccine Alliance, where she has influenced vaccine financing, policy development, and global immunization strategies.
In her current role as Director, Immunization, Vaccines and Biologicals for the World Health Organization (WHO), O'Brien leads the global vaccine and immunization strategy. She oversees WHO's work across the vaccine continuum by accelerating new vaccine research and development, advancing vaccine access and equity, introducing new vaccines into country programs, identifying and responding to outbreaks including as WHO's vaccine technical lead during the COVID-19 pandemic, and strengthening immunization program reach in order to maximize the impact of vaccines, even in the most fragile and vulnerable settings.
O'Brien earned her medical degree from McGill University and a Master of Public Health from Johns Hopkins University. She completed her pediatric and infectious disease training at Johns Hopkins Medical Institutions and served as an Epidemic Intelligence Service officer at the U.S. Centers for Disease Control and Prevention (CDC).
'I am deeply grateful for a career working with incredible people around the world, and through them to have life-saving impact,' says O'Brien. 'Vaccines are truly one of science's greatest achievements. It is immensely fulfilling to work on vaccines all the way from development through licensure and dissemination, and to then see them protect the lives and well-being of families. This award is a huge honor, and a tribute to those who have taught me the value of evidence-based courage.'
Sabin's Rising Star Award is intended to encourage and recognize the next generation of vaccine and immunization leaders. Mbianke is a dedicated physician and public health specialist whose work in vaccine access and strengthening health systems has made a profound impact on underserved communities. With expertise in immunization, maternal and child health, and community engagement, Mbianke has played a pivotal role in expanding vaccine coverage and improving health outcomes in Cameroon.
'With his recognized achievements in reducing maternal and child mortality by 50% in remote areas and increasing accessibility of vaccines, Dr. Mbianke is leading innovations around immunization in fragile settings,' says Finan. 'Whether he is delivering vaccines to displaced populations or creating health clinics out of village councils, his creative solutions serve as a model for those working in challenging settings and makes him a Rising Star in global health.'
As Program Country Manager for the COMBAT Project (Community-Based Tracking for Immunization) at the International Vaccine Access Center (IVAC), Mbianke leads efforts to enhance immunization delivery by improving community-based monitoring, engagement, and service delivery strategies. He also serves as Technical Advisor for the World Health Organization's 'Big Catch-Up,' a global initiative aimed at restoring vaccine coverage following pandemic-related disruptions.
Beyond his advisory roles, Mbianke is the CEO of Empower Women Foundation, where he champions maternal and child health initiatives in Cameroon, advocating for sustainable and locally driven health care solutions. His leadership extends to past roles with WHO, Gavi, USAID, and other global health organizations, where he has contributed to immunization policy formulation and innovative strategies to reach zero-dose and under-immunized children.
A graduate of Université de la Montagne Bagante (MD) and Mountain University for Sustainable Studies (MPH), Mbianke combines medical expertise with public health leadership to promote vaccine confidence and equitable access.
'This award is so meaningful,' says Mbianke. 'When you work in settings with such a high burden, sometimes you feel you are not doing enough because you want to improve as many lives as possible. But recognition like the Rising Star award really motivates you. It says you are creating an impact. You are creating a change.'
Awarded annually since 1993 and 2020 respectively, the Albert B. Sabin Gold Medal and Rising Star Award honor individuals who have made extraordinary contributions to immunization and global health. These awards commemorate the legacy of the late Dr. Albert B. Sabin, who discovered the oral polio vaccine and dedicated his life to ensuring everyone in the world had access to vaccines.
Watch the 2025 Albert B. Sabin Gold Medal and Rising Star ceremony on Sabin's YouTube channel.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on X @SabinVaccine.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Systemic Sclerosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Systemic Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Systemic Sclerosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Sclerosis Pipeline Outlook Key Takeaways from the Systemic Sclerosis Pipeline Report In June 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. In June 2025, GlaxoSmithKline conducted a study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life. DelveInsight's Systemic Sclerosis Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Systemic Sclerosis treatment. The leading Systemic Sclerosis Companies such as Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others. Stay ahead with the most recent pipeline outlook for Systemic Sclerosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Systemic Sclerosis Treatment Drugs Systemic Sclerosis Emerging Drugs Profile Iloprost: Eicos Sciences Iloprost is a stable analogue of PGI2 and a potent prostacyclin (IP) receptor agonist. By mimicking PGI2, it is a vasodilator and inhibitor of platelet activation and fibrosis. Iloprost stimulates generation of cAMP by binding to the IP receptor, thereby affecting phospholipase activity and cytosolic calcium levels in platelets, fibroblasts, and endothelial cells. It is a potent vasodilator and platelet inhibitor with anti-inflammatory and anti-fibrotic effects being developed and investigated in Phase III stage of development for the treatment of digital ischemic episodes in people with Systemic Sclerosis (SSc). ECCS 50: Cytori therapeutics ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient's fat tissue and reinjecting these cells into the hands. ECCS 50 are adipose derived stem and regenerative cells (ADRCs) taken from the patient's own tissue and prepared using Cytori's cellulation system before administration. ADRCs can be used to repair and regenerate a range of damaged or diseased tissue types by differentiation of the ASRCs along the specific cell lineage, thereby replacing the damaged or missing tissue. Lenabasum (JBT-101): Corbus Pharmaceuticals Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles without evidence of immunosuppression. EHP-101: Emerald Health Pharmaceuticals EHP-101 is an oral formulation of VCE-004.8, a synthetic aminoquinone derivative of CBD with dual peroxisome proliferator-activated receptor gamma (PPARγ) and cannabinoid receptor type 2 (CB2) agonist activity. Both receptors are therapeutic targets for SSc. EHP-101 also modulates the hypoxia inducible factor (HIF) pathway, expanding the rationale for its development as a novel SSc drug. It is currently in phase II stage of development and is being developed by Emerald Health Pharmaceuticals. The Systemic Sclerosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Sclerosis Treatment. Systemic Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Systemic Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Sclerosis market Explore groundbreaking therapies and clinical trials in the Systemic Sclerosis Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Systemic Sclerosis Drugs Systemic Sclerosis Companies Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Systemic Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Molecule Type Systemic Sclerosis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Systemic Sclerosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Sclerosis Market Drivers and Barriers Scope of the Systemic Sclerosis Pipeline Report Coverage- Global Systemic Sclerosis Companies- Eicos Sciences, Beijing Continent Pharmaceutical, Kyowa Kirin, Cytori Therapeutics, Corbus Pharmaceuticals, Zenyaku Kogyo, Sanofi, Bayer, ASKA Pharmaceutical, Emerald Health Pharmaceuticals, United Therapeutics, Cumberland Pharmaceuticals, ILTOO Pharma, Horizon Pharmaceuticals, Janssen Biotech, Gesynta Pharma, Certa Therapeutics, Pfizer, Vicore Pharma, Seagen, CSL Behring, arGentis Pharmaceuticals, Mitsubishi Tanabe Pharma, Kadmon Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Camurus, Regeneron Pharmaceuticals, Castle Creek Biosciences, Talaris Therapeutics, Viela Bio, Formation Biologics, Horizon Therapeutics, Chemomab Therapeutics, AnaMar, Atlantic Healthcare, D&D Pharmatech, Acceleron Pharma, Riptide Bioscience, Timber Pharmaceuticals, Tvardi Therapeutics, Accuitis Pharmaceuticals, AKL Research and Development, iBio, Blade Therapeutics, Cantargia, BriaCell Therapeutics, Leadiant Biosciences and others. Systemic Sclerosis Pipeline Therapies- Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, Riociguat (Adempas, BAY63-2521), Bosentan, Imatinib mesylate, Belimumab, Rituximab, and others. Systemic Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Systemic Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Systemic Sclerosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Sclerosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Systemic Sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) Iloprost: Eicos Sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) EHP-101: Emerald Health Pharmaceuticals Drug profiles in the detailed report….. Early stage products (Phase I) VIB7734: Viela Bio Drug profiles in the detailed report….. Inactive Products Systemic Sclerosis Key Companies Systemic Sclerosis Key Products Systemic Sclerosis- Unmet Needs Systemic Sclerosis- Market Drivers and Barriers Systemic Sclerosis- Future Perspectives and Conclusion Systemic Sclerosis Analyst Views Systemic Sclerosis Key Companies 23. Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Globe and Mail
3 hours ago
- Globe and Mail
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. 'Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,' said Paul Clancy, chair of the board of directors of Xilio Therapeutics. 'With over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde's extensive expertise as we advance toward the clinic with XTX501, our masked PD-1/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.' 'Xilio's innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,' said Dr. Bello. 'I am honored to join Xilio's board of directors at this important time and look forward to contributing to Xilio's efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.' Akintunde Bello, Ph.D. Dr. Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers and tumor-selective molecules. He most recently served as senior vice president, head of clinical pharmacology, pharmacometrics and bioanalysis at Bristol Myers Squibb Company (BMS) until his retirement in 2025. While at BMS, Dr. Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Prior to BMS, Dr. Bello spent more than a decade with Pfizer Inc. (Pfizer), where he was responsible for overseeing clinical pharmacology for Pfizer's late-stage oncology development programs. Dr. Bello received a in biomedical sciences from Portsmouth Polytechnic, an in instrumentation and analytical science from University of Manchester and a Ph.D. in pharmaceutical sciences from King's College, University of London. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding achievement of key milestones; and the potential benefits of any of Xilio's current or future product candidates in treating patients; and Xilio's strategy, goals, business plans and focus. The words 'aim,' 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'seek,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio's current or future product candidates; Xilio's ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio's advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio's product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio's ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio's ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio's business, including U.S. and China trade policies; Xilio's ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio's ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled 'Risk Factor Summary' and 'Risk Factors' in Xilio's filings with the U.S. Securities and Exchange Commission (SEC), including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Globe and Mail
3 hours ago
- Globe and Mail
Cohere launches AI health care agents in the U.S.
Canadian artificial intelligence company Cohere Inc. is entering the health care industry through a partnership with U.S.-based Ensemble Health Partners that uses AI agents to help hospitals and other providers manage their revenue. Cohere, founded in 2019, uses large-language models to build chatbots and generative-AI platforms for enterprise customers to automate some tasks. The partnership with Ensemble, launched Tuesday, uses a customized version of the North by Cohere platform that will run on health care providers' internal systems and help with tasks such as hospitals appealing insurance-claim denials and chasing down accounts receivable. The company said pre-launch tests of the tools accelerated denial appeals by 40 per cent and improved denial overturn rates by 15 per cent. Running on internal systems is a key part of how the AI system protects the safety of patients' information and complies with privacy law, said Cohere co-founder Ivan Zhang. 'There's no data leaving their system, because all the agents are in the house,' he said. Because of those privacy concerns, Mr. Zhang said the AI has to be trained on synthetic data, which would be similar to real-world data in likeness and structure but without any protected personal information. The foray into health-care follows Cohere's work in the financial sector, which has to adhere to similar privacy rules. In January, the company announced a partnership with Royal Bank of Canada to co-develop and run a customized platform called North for Banking which, among other things, helps employees answer questions from customers. Mr. Zhang said Cohere is focused on the U.S. market for now, but hopes to have more to announce for Canadian health-care soon. 'So far, we are focused on the U.S. markets. We want to take these learnings and adapt it to different systems in Canada and globally,' he said. Cohere did not disclose any financial terms or which U.S. clients are using the AI platform. The company also received a nod Tuesday from new federal AI minister Evan Solomon. In a speech in Ottawa, Mr. Solomon outlined the government's new approach to AI, saying it would shift from 'warnings and regulation' to celebrating industry 'champions' such as Cohere. Mr. Zhang said he was 'delighted' by the support and said there was a strong case to be made that investments in AI were part of strengthening Canada's economy and security. 'We've been very happy about the government's engagement so far,' he said.